|
FDA Proposes Enhancing Search Criteria for Inspections Database
|
|
|
| By
Erik Greb
|
|
|
|
FDA may consider whether to add specific search criteria (e.g., those that would enable product-specific or violation-specific searches) to its inspections database to make it user-friendly and improve data analysis. The idea was included in a list of eight draft proposals for increasing transparency that the agency published on Oct. 3, 2011.
|
|
|
|
Private Equity Firms to Acquire PPD for $3.9 Billion
|
|
|
| By
Amy Ritter
|
|
|
|
The CRO Pharmaceutical Product Development (PPD) will be acquired by the Carlyle Group and Hellman and Friedman in a deal valued at approximately $3.9 billion. PPD shareholders will receive $33.25 per share in cash, and PPD will become a privately held company after completion of the transaction.
|
|
|
|
EMA Invites Feedback on Biosimilar and Vaccine Concept Papers
|
|
|
| By
Rich Whitworth
|
|
|
|
EMA released two concept papers for consultation that address the need to revise existing guidelines on biosimilar medicines and influenza vaccines.
|
|
|
|
Takeda Completes Nycomed Acquisition
|
|
|
| By
Stephanie Sutton
|
|
|
|
Takeda Pharmaceutical Company has completed its acquisition of Nycomed for EUR 9.6 billion ($12.9 billion) on a cash-free, debt-free basis. In addition, Takeda has named Frank Morich, Takeda's executive vice-president of internal operations (Americas/Europe), as Nycomed's CEO.
|
|
|
|
Servier and Galapagos Form Cancer Collaboration
|
|
|
| By
Stephanie Sutton
|
|
|
|
Servier and the Belgium-based biotechnology company Galapagos are embarking on a multiyear strategic alliance to develop new cancer therapies. As a result of the alliance, Galapagos could receive milestone payments of more than EUR 250 million ($332 million).
|
|
|
|
Week of Oct. 3, 2011: Merck Serono and Ono Pharmaceutical Sign MS, Cancer Pacts; Roche Names Rainer Metternich Head of Small-Molecule Research; and More
|
|
|
|
Merck Serono and Ono Pharmaceutical Sign MS, Cancer Pacts; Roche Names Rainer Metternich Head of Small-Molecule Research; and More.
|
|
|
